The report provides a detailed analysis essential for establishing a Dexmedetomidine production plant. It encompasses all critical aspects necessary for Dexmedetomidine production, including the cost of Dexmedetomidine production, Dexmedetomidine plant cost, Dexmedetomidine production costs, and the overall Dexmedetomidine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Dexmedetomidine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Dexmedetomidine is an FDA-approved non-narcotic analgesic that finds huge applications in the medical industry. The drug is widely used to induce sedation for a short period to facilitate certain surgical procedures of intubated and mechanically ventilated patients. Moreover, it also finds its application as an analgesic drug that can also be given to children under anesthesia to relieve pain and reduce agitation due to surgery. Additionally, it is also employed in the management of pain and peri-operative sedation of non-intubated patients, which helps in managing anxiety agitation and promotes recovery. This drug can also be used for relieving pain and inducing sedation in animals during diagnostic procedures or surgeries.
The market for Dexmedetomidine is primarily driven as a sedative drug used in hospitals and surgical settings for sedation during surgeries, especially in intensive care units (ICUs), which remarkably contributes to its demand. Its employment as a sedative for animals during surgeries notably promotes its demand in the veterinary medicine industry. Moreover, its usage as a non-narcotic analgesic drug for the sedation of critically ill patients in ICUs and pediatric patients under sedation further enhances its demand in the medical, healthcare, and pharmaceutical industries. Additionally, several factors, such as the availability of raw materials (2,3-dimethylbenzoyl chloride, tartaric acid, etc.), pricing, its applications as a sedative, employment in animal surgeries, and quality standards, significantly influence industrial Dexmedetomidine procurement globally.
Raw Material for Dexmedetomidine Production
According to the Dexmedetomidine production plant project report, the major raw materials for Dexmedetomidine production include 2,3-dimethylbenzoyl chloride and 1-N,N-dimethyl sulfonyl-2-(tert-butyldimethylsily)-5-(2,3-dimethyl benzoyl) imidazole and Monomethylamine and Tartaric Acid.
Production Process of Dexmedetomidine
The extensive Dexmedetomidine production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: This method of production is initiated by the reaction of 2,3-dimethylbenzoyl chloride and 1-N,N-dimethyl sulfonyl-2-(tert-butyldimethylsily)-5-(2,3-dimethyl benzoyl) imidazole in the presence of hydrochloric acid to give an intermediate, 4(5)-(2,3-dimethyl benzoyl) imidazole. Further, the obtained intermediate compound undergoes reduction by using monomethylamine to obtain medetomidine, followed by its resolution under the action of tartaric acid, which results in the formation of dexmedetomidine as the final product.
Dexmedetomidine is a derivative of imidazole and an active isomer of medetomidine with analgesic properties. The IUPAC name of the compound is 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole. It is also known as Dexmedetomidinum. The molecular formula of the compound is C13H16N2, and its molar mass is 200.28 g/mol. Moreover, the boiling point of the compound is 381.9 °C, and its melting point is 146-149°C. The density of the compound is 1.053 g/cm3 at 20 °C.
Additionally, the compound exists in the form of white solid that is stored at room temperature and sealed in a dry place. The drug is marketed under the brand names Dexdor and Precedex. The compound might cause some side effects, such as lower heart rates, pain at the injection site, and headache.
